IPM Take
This is where guideline elegance collides with real life. Radiation omission is increasingly attractive in selected low-risk ER-positive breast cancer, but many protocols rely on sustained endocrine therapy. If adherence collapses after the treatment decision is made, the risk model changes. De-escalation needs navigation and follow-up, not simply fewer appointments.
Executive Summary
A nationwide U.S. claims analysis presented at ASTRO evaluated 17,025 women with estrogen receptor-positive early-stage breast cancer treated with lumpectomy and prescribed endocrine therapy; 89% received adjuvant radiotherapy. Using the conventional medication possession ratio threshold of at least 80%, fewer than 30% remained adherent at five years in time-to-event analysis. Among older patients, omission of radiotherapy was associated with a higher risk of endocrine-therapy non-adherence. The investigators cautioned that radiation-omission strategies often assume sustained endocrine therapy, while real-world behaviour may be substantially different.
Why it matters
- Patients / advocates: Endocrine therapy can carry persistent side effects that make five years of treatment difficult.
- Clinicians: Radiation-omission discussions should include realistic assessment of likely endocrine adherence.
- Hospitals / providers: De-escalation requires follow-up systems capable of detecting when the replacement treatment is quietly being abandoned.
- Payers / public authorities: Fewer radiotherapy visits do not automatically equal better value if downstream recurrence risk rises because endocrine therapy is not sustained.
De-escalation sounds simple when written into a guideline.
Omit radiation. Continue endocrine therapy. Monitor.
Real patients are less tidy.
The ASTRO analysis looked at more than 17,000 women with ER-positive early breast cancer after lumpectomy. Fewer than three in ten remained above the standard adherence threshold for endocrine therapy across five years.
That matters because some of the most influential breast-cancer de-escalation trials use endocrine therapy as the other half of the bargain.
Radiotherapy can be safely omitted in carefully selected older patients with favourable disease. But the evidence behind that decision generally assumes that endocrine therapy continues.
What happens when it does not?
That is not a reason to irradiate everyone. It is a reason to stop pretending treatment decisions exist independently of treatment behaviour.
Endocrine therapy can cause hot flushes, joint symptoms, sexual dysfunction, sleep disturbance and other effects that accumulate over years. A five-minute conversation at the end of radiation decision-making does not guarantee five years of adherence.
Interestingly, among older patients in this study, those who received radiation were less likely to become non-adherent to endocrine therapy. The study cannot prove why. It may reflect treatment selection, patient behaviour, healthcare engagement or unmeasured factors. But the association is important enough to complicate the clean narrative around omission.
This is what real-world evidence is supposed to do.
Not destroy de-escalation.
Make it honest.
A patient considering omission of radiation should not only be asked whether her tumour qualifies.
The system should also ask whether it can support her through the therapy the de-escalated strategy depends on.
